Angina Pectoris Drugs Market Size & Share 2026-2035

Angina Pectoris Drugs Market Size

The angina pectoris drugs market estimated at USD 12.6 billion in 2025. The market is expected to grow from USD 13 billion in 2026 to USD 19.1 billion in 2035, growing at a CAGR of 4.3% during the forecast period, according to the latest report published by Global Market Insights Inc.

Moreover, the growing prevalence of lifestyle-related risk factors such as obesity, sedentary behavior, unhealthy diets, smoking, and stress are contributing to the rise in cardiovascular diseases, including angina, by increasing the prevalence of conditions like high blood pressure and diabetes. As modern lifestyles continue to lead to poor heart health, more individuals are at risk of angina, driving the demand for treatments.
 

Angina pectoris drugs refer to a class of drugs used for the treatment of chest pain and the improvement of heart functions through increased blood flow or the reduction of oxygen demand by the heart. The different types of drugs used in the treatment of angina pectoris include nitrates, beta-blockers, calcium channel blockers, anticoagulants, and antiplatelet drugs. These drugs alleviate symptoms, prevent episodes, and reduce the risk of severe cardiovascular events. Key players such as AstraZeneca, Pfizer, Novartis, Bayer, and Sanofi contribute to the growth of the market through increased R&D in cardiovascular diseases, extension of their angina and anti-ischemic drugs portfolio, and strategic business collaborations to enhance their distribution network worldwide.
 

During this period, from 2022 to 2024, the global angina pectoris drugs market size grew from USD 11.7 billion in 2022 to USD 12.3 billion in 2024, owing to the increasing geriatric population, who are more prone to coronary artery diseases and chronic angina. Additionally, better diagnostic techniques and early detection of the disease enabled timely treatment initiation, while increased adoption of combination therapies enhanced clinical outcomes and prescription volumes, thereby contributing to the market growth.
 

Angina Pectoris Drugs Market Trends

The angina pectoris drugs industry is being influenced by a variety of converging trends, which are resulting in sustained growth for the market.
 

• The market is witnessing a surge in pipeline development and clinical-stage innovation, as manufacturers are focusing on developing new anti-anginal drug therapies to meet clinical needs. One such company is Auxilius Pharma, which has planned to file an IND for AUX-001 and start a Phase Ib study for the treatment of chronic stable angina pectoris by March 2024. This indicates an increase in drug development, leading to an increase in therapeutic options and hence fueling growth for the market.
   
• Additionally, the rise of generic drug penetration has made treatment more affordable, expanded patient access, and increased prescription volumes, particularly in emerging markets, following the expiration of patents for several branded cardiovascular drugs. At the same time, advancements in drug formulations and drug delivery systems are resulting in better patient compliance, reduced side effects, and higher therapeutic efficacy, thus fueling growth for the market.
   
• Further, early diagnosis and better cardiovascular screening by means of advanced imaging, biomarker analysis, and stress testing have paved the way for early intervention. By detecting the disease early, doctors can administer treatment sooner which leads to better patient outcomes and an increase in prescription rates, thereby raising the market demand.
   
• Another trend contributing to the growth of the market is the rise in healthcare infrastructure and telemedicine services that are enhancing access to cardiovascular therapies, especially in emerging economies. Remote monitoring, digital adherence tools, and telecardiology are helping in long-term disease management and personalized therapy plans, thus contributing to the growth of the angina pectoris drugs market.
   
• Moreover, there is a rising trend of using combination and adjunctive therapies in which multiple drug regimens are being used for the management of symptoms and prevention of cardiovascular events. Fixed dose are also helping in the enhancement of patient compliance.
   
• Furthermore, educational programs that focus on wellness are promoting early compliance with drug therapy, thereby indirectly fueling the demand for drug therapy, thereby contributing to the growth of the market.
   
• Overall, these trends are collectively enhancing treatment accessibility, improving patient outcomes, fostering innovation, and expanding market reach, thereby driving sustained growth in the market.
   

Angina Pectoris Drugs Market Analysis

Based on the type, the market is segmented into stable angina, unstable angina, microvascular angina, and prinzmetal angina. The stable angina segment accounted for significant market share of 51.5% in 2025.
 

• Stable angina is the most prevalent type of angina that causes chest pain mostly due to exercise or emotional stress. The high prevalence rate of stable angina pectoris in patients suffering from coronary artery disease has contributed to its high share in the global angina pectoris drug market.
   
• Secondly, the availability of well-established treatment protocols, such as nitrates, beta blockers, and calcium channel blockers enables effective treatment that helps increases the adoption of drugs.
   
• Additionally, increasing awareness and better diagnostic tools have resulted in a rise in the number of cases diagnosed, which has also contributed to the growth of the segment.
   
• On the other hand, unstable angina segment is expected to grow at 4.6% of CAGR during the forecast period. The rising prevalence of cardiovascular diseases, particularly among aging populations and individuals with risk factors such as hypertension, diabetes, obesity, and smoking, is increasing the number of diagnosed unstable angina cases. This growing patient pool is contributing to the steady demand for effective drug therapies.
   
• Additionally, advancements in antiplatelet agents, anticoagulants, beta-blockers, and nitrates, along with improved emergency care protocols, are supporting the adoption of pharmacological treatments for unstable angina.
   

Based on the drug class, the global angina pectoris drugs market is categorized into beta blockers, nitrates, anti-platelets, calcium channel blockers, anticoagulants, ACE inhibitors, and other drug classes. The beta blockers segment was valued at USD 3.8 billion in 2025.
 

• Beta blockers are considered primary therapy for angina pectoris, especially stable angina, as they effectively reduce heart rate, lower myocardial oxygen demand, and improve exercise tolerance.
   
• Additionally, their broad clinical application and proven efficacy make them a cornerstone of angina treatment.
   
• The growth of the segment is further supported by the rising incidences of cardiovascular risk factors such as hypertension and coronary artery diseases, where beta blockers are commonly prescribed.
   
• On the other hand, the nitrates segment is projected to grow at 4.8% CAGR over the coming years due to their widespread use in the management of angina pectoris and other cardiovascular conditions.
   
• Furthermore, nitrates are commonly used in the management of acute and chronic symptoms of angina, and in combination with other cardiovascular drugs. Their established efficacy, relatively low cost, and availability in multiple formulations such as tablets, sprays, and patches contribute to their continued market growth.
   

Based on the route of administration, the global angina pectoris drugs market is divided into oral, injectable and topical. The oral segment dominated the market in 2025, and is expected to grow at 4.4% CAGR over the analysis period.
 

• Most first-line treatments for angina, such as beta blockers, nitrates, and calcium channel blockers, are available in oral formulations, ensuring wide accessibility. 
   
• Oral medications generally have lower production and distribution costs, making them more affordable for both healthcare systems and patients.
   
• Additionally, angina pectoris often requires long-term treatment, making oral drugs ideal for daily use without the need for clinical visits.
   
• Owing to the above-mentioned factors the oral segment is anticipated to witness growth in coming years.

• Hospitals provide direct access to specialized care, including advanced drug formulations, injectable therapies, and comprehensive treatment plans tailored to patients with unstable angina or comorbidities. The ability to offer urgent care and high-strength medications ensures hospital pharmacies are crucial in treating severe angina cases, thereby driving their market share.
   
• Moreover, the rising rate of cardiovascular diseases is resulting in a rise in hospitalizations for angina-related complications, thus propelling the demand for medications procured from hospital pharmacies.
   
• On the other hand, the online pharmacies segment is expected to witness significant growth at 4.7% CAGR owing to an increase in digital health platforms and consumer preference for convenient ways of procuring medication.

North America Angina Pectoris Drugs Market

The North America held around 41.2% of the angina pectoris drugs industry share in 2025 in and is anticipated to expand at 4.2% CAGR over the forecast period.
  

• North America dominates the market due to the high prevalence of cardiovascular diseases, a well-established healthcare infrastructure, and strong adoption of advanced pharmacological treatments.
   
• The presence of leading pharmaceutical companies, significant healthcare expenditure, and increasing awareness regarding early diagnosis and management of coronary artery diseases further support market growth.
   
• Additionally, favorable reimbursement policies, ongoing clinical research, and the availability of innovative drug therapies contribute to the sustained demand for angina pectoris drugs across the region.
   

The U.S. angina pectoris drugs market reached USD 4.8 billion in 2025 from USD 4.6 billion in 2024.
 

• According to the National Institutes of Health, about 10 million people in the U.S. have angina, a major symptom of coronary artery disease, and approximately 500,000 new cases are diagnosed each year. This high and increasing prevalence drives the demand for effective medications to manage angina, contributing to the market's substantial value.
   
• Additionally, the U.S. leads in medical research, with continuous innovations in angina therapies, such as beta blockers, nitrates, and advanced combination treatments. These advancements offer more effective treatment options, which drive market growth.
   

Europe Angina Pectoris Drugs Market

The Europe market was valued at USD 3.6 billion in 2025 and is anticipated to witness strong growth over the forecast period.
 

• Europe accounts for a significant share of the global angina pectoris drugs industry due to increasing adoption of combination drug therapies and improved treatment adherence among patients with chronic cardiovascular conditions.
   
• The region also benefits from structured clinical guidelines for angina management and widespread use of preventive cardiology practices.
   
• Additionally, ongoing collaborations between research institutions and pharmaceutical companies, along with expanding availability of generic cardiovascular drugs, support consistent market demand across European healthcare systems.
   

Germany angina pectoris drugs market is predicted to witness remarkable growth over coming years.
 

• Germany has one of the most rapidly aging populations in Europe, with a significant portion of the population over the age of 65. As cardiovascular diseases, including angina, are more common among older individuals, the aging demographic will continue to increase the demand for angina medications.
   
• Further, the country is known for its highly advanced healthcare infrastructure, with access to high-quality medical treatments and medications. The availability of cutting-edge treatments and widespread adoption of new therapies in the healthcare system are factors that contribute to the market growth.
   

Asia Pacific Angina Pectoris Drugs Market

The Asia Pacific market is expected to grow in coming years at CAGR of 4.7%.
 

• The growth of this region is majorly supported by the rapidly aging population and increasing cardiovascular disease burden. According to the Asian Development Bank, by 2050, one in four people in Asia and the Pacific will be aged over 60, and the elderly population is projected to triple from 2010 levels to nearly 1.3 billion people. Since aging significantly increases the risk of coronary artery disease and angina, this demographic shift is expected to drive higher demand for anti-anginal medications across the region.
   
• Additionally, government initiatives to improve cardiovascular healthcare infrastructure and expand access to essential medicines are expected to drive increased adoption of angina pectoris drugs throughout the region.
   

India is projected to grow significantly during the forecast period.
 

• The growth of this market is attributed to the increasing prevalence of cardiovascular diseases, driven by rising obesity rates, diabetes, hypertension, and lifestyle factors such as unhealthy diets and sedentary habits.
   
• Additionally, improved healthcare infrastructure, greater healthcare awareness, and government initiatives like Ayushman Bharat are making angina treatments more accessible across the country, particularly in rural areas.
   

Latin America Angina Pectoris Drugs Market

Brazil's market is expected to experience growth over the analysis period.
 

• Brazil's aging population is contributing to a higher number of people suffering from age-related cardiovascular conditions like angina. As the proportion of elderly individuals rises, more people will require medications to manage their heart health.
   
• Additionally, the country is working towards expanding its healthcare system through programs like SUS (Sistema Único de Saúde), which provides affordable healthcare to a significant portion of the population. This will increase accessibility to angina treatments, leading to market growth.
   

Middle East & Africa Angina Pectoris Drugs Market

Saudi Arabia market is poised to grow in coming years.
 

• As Saudi Arabia continues to urbanize, lifestyle changes like reduced physical activity and unhealthy eating habits are contributing to the growth of cardiovascular diseases. This urbanization trend is expected to boost the demand for angina treatments.
   
• Additionally, factors such as increased awareness and focus on preventive care, government healthcare initiatives, and growing prevalence of cardiovascular diseases further support the growth of this market.
   

Angina Pectoris Drugs Market Share

The angina pectoris drugs industry is highly competitive, with several global pharmaceutical companies leading the market. Key players such as AstraZeneca, Pfizer, Novartis, Bayer, and Sanofi, dominated the global market and collectively accounted for 52% of market share in 2025. These companies are continuously investing in research and development to introduce new and improved treatments for angina, addressing the evolving needs of patients. With the increasing focus on cardiovascular health, partnerships and collaborations between pharmaceutical companies, healthcare providers, and research institutions are likely to drive innovation and contribute to the market's growth in the coming years.
 

Key players are expanding their portfolios through the development of next-generation anti-anginal therapies, while also enhancing distribution networks and patient support programs. Additionally, increasing investment in cardiovascular clinical trials and R&D enables companies to address unmet medical needs, differentiate their offerings, and capture a larger share of the growing global market.
 

Angina Pectoris Drugs Market Companies

Prominent players operating in the global angina pectoris drugs industry include:

• AdvaCare Pharma
• Amgen
• AstraZeneca
• Bayer
• Boehringer Ingelheim International
• Cadila Pharmaceuticals
• Eli Lilly and Company
• Gilead Sciences
• GlaxoSmithKline
• Merck
• Novartis
• Otsuka Pharmaceutical
• Pfizer
• Sanofi
   

AstraZeneca

AstraZeneca is a leading player in the angina pectoris drugs market, accounting for a significant share of 20.7% due to its strong cardiovascular portfolio, including branded anti-anginal therapies. The company leverages robust R&D capabilities and extensive global distribution networks to enhance accessibility, maintain high prescription volumes, and support steady market growth.
 

Pfizer

Pfizer contributes to market expansion with its diversified cardiovascular product offerings, including innovative anti-anginal therapies. The company’s strong brand recognition, widespread presence across hospital and retail pharmacies, and ongoing investment in clinical development reinforce its market leadership.
 

Sanofi

Sanofi plays a key role in the angina pectoris drugs market through its well-established cardiovascular portfolio and focus on patient-centric therapies. Its strategic partnerships, global distribution channels, and strong physician engagement programs help drive adoption, accessibility, and sustained demand for its anti-anginal treatments.
 

Angina Pectoris Drugs Industry News

• In December 2025, Auxilius Pharma secured a USD 4 million Series A funding round to fast-track the development of its chronic stable angina therapy, AUX-001, a once-daily formulation aimed at both treating and preventing chronic stable angina. This financing enabled the company to accelerate clinical trials, expand R&D capabilities, and strengthen its position in the anti-anginal therapies market, supporting faster progression toward regulatory approval and commercialization.
   
• In November 2025, Alembic Pharmaceuticals announced that it had received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride Tablets, a generic equivalent of Cardizem marketed by Bausch Health US, LLC. The drug, which is indicated for the management of chronic stable angina and angina due to coronary artery spasm. This approval allowed the company to enter the U.S. cardiovascular generics market, expand revenue streams, and strengthen its global market presence.
   
• In June 2025, Cadila Pharmaceuticals launched Biscado (Bisoprolol), marking its foray into the beta-blocker segment for managing cardiovascular conditions in India. Bisoprolol, a beta-1 adrenergic blocker, is indicated for hypertension, angina, and chronic heart failure. This launch enabled the company to expand its cardiovascular portfolio, capture a larger share of the growing anti-hypertensive and anti-anginal market, and strengthen its position in the Indian healthcare sector.
   
• In August 2025, Zydus Lifesciences received USFDA approval to market Diltiazem Hydrochloride tablets in 30 mg, 60 mg, 90 mg, and 120 mg strengths for the treatment of angina and hypertension. This approval allowed Zydus Lifesciences to enter the U.S. cardiovascular market, enhance its product portfolio, and generate new revenue opportunities in the high-demand anti-anginal segment.
   

The angina pectoris drugs market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Stable angina
• Unstable angina
• Microvascular angina
• Prinzmetal angina

Market, By Drug Class

• Beta blockers
• Nitrates
• Anti-platelets
• Calcium channel blockers
• Anticoagulants
• ACE inhibitors
• Other drug classes

Market, By Route of Administration

• Oral
• Injectable
• Topical

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE